United Orthopedic Corporation is now enrolling patients in its follow-up study of the U-Motion II+ Acetabular System and UTF Reduced Stem in patients receiving primary total hip arthroplasty.
Here are five notes:
1. Through the study, United Orthopedic intends to analyze the short and long-term clinical performance of the devices.
2. The U-Motion II+ Acetabular System and UTF Reduced Stem aim to improve hip flexion, minimize the risk of joint dislocation and reduce bone removal during THAs.
3. Kurtis Biggs, DO, implanted the first U-Motion II+ Acetabular System and UTF Reduced Stem on a patient enrolled in the study in January 2016. Dr. Biggs is the founder of Naples-Fla.-based Joint Replacement Institute.
4. UO intends to enroll up to 200 patients in the study at a maximum of five sites throughout the United States.
5. The devices use a coating technology that works to achieve a greater surface roughness of the implant, allowing for enhanced stability and reduced micromotion.
More articles on devices:
Bioventus gets rights to distribute GELSYN-3 in the US: 5 key notes
Nihon Kohden launches Neuromaster MEE-2000A — 5 highlights
OrthoGrid Systems releases HipGrid Drone: 4 notes